Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07647224

A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Multiple Dose Healthy Adult Participants

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Beijing Tongren Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, 100730, China

Location contact

Assistant project manager

CONTACT

[email protected]

021-50805988-8039

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • BMI 19.0-28.0 kg/m², with male subjects weighing ≥50.0 kg and female subjects weighing ≥45.0 kg；
  • Understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and sign the informed consent form.

Main Exclusion Criteria:

  • A history of past or current conditions involving the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, endocrine system, metabolic system, or other clearly documented medical conditions, which the investigator deems may pose a risk to the subject's safety or interfere with the conduct, progress, or completion of the trial.
  • History of drug use or substance abuse, or positive urine drug screening prior to enrollment.
  • Pregnant and breastfeeding women.

Treatment and study plan

GR2301 injection

Drug

IL15 monoclonal antibody

Primary outcomes

  1. Adverse events (AEs)

    Time frame: Up to 52 Weeks

    Incidence of AEs

Secondary outcomes

  1. Pharmacokinetics parameters

    Time frame: Up to 52 weeks

    concentration of GR2301

  2. Incidence of ADA.

    Time frame: Up to 52 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

liaison officer

CONTACT

[email protected]

021-50805988-8039

Sponsors and collaborators

Lead sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 15, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.